The European Union (EU) executive committee has officially approved the conditional sale of the COVID-19 vaccine jointly developed by multinational pharmaceutical company AstraZeneca and the University of Oxford in the UK.
On the 29th local time, executive chairman Ursula Ponderrayen tweeted, “I expect the company to deliver 400 million batches as agreed.” “We will continue to do everything we can to secure it.”
This is the third COVID-19 vaccine approved by the European Medicines Agency (EMA) for conditional use in the EU, following a vaccine developed by US pharmaceutical companies Pfizer-German Bioentech and US Modena.
The EU has signed a contract to purchase 400 million vaccine doses with AstraZeneca on behalf of the member states.
–
Article reporting and press release provided [email protected]
copyright© tbs. Unauthorized reproduction & redistribution prohibited
